Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-02-19
2011-12-20
Saeed, Kamal (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S443000, C514S475000, C548S465000, C549S058000, C549S548000
Reexamination Certificate
active
08080576
ABSTRACT:
One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
REFERENCES:
patent: 4733665 (1988-03-01), Palmaz
patent: 5071957 (1991-12-01), Konishi et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5340736 (1994-08-01), Goldberg
patent: 5376645 (1994-12-01), Stella et al.
patent: 5441944 (1995-08-01), Weisz et al.
patent: 5874418 (1999-02-01), Stella et al.
patent: 6046177 (2000-04-01), Stella et al.
patent: 6099851 (2000-08-01), Weisman et al.
patent: 6133248 (2000-10-01), Stella
patent: 6204257 (2001-03-01), Stella et al.
patent: 6235717 (2001-05-01), Leban et al.
patent: 6410512 (2002-06-01), Mundy et al.
patent: 6462019 (2002-10-01), Mundy et al.
patent: 6492333 (2002-12-01), Mundy
patent: 6613541 (2003-09-01), Vaddi et al.
patent: 6617309 (2003-09-01), Tung et al.
patent: 6656904 (2003-12-01), Mundy et al.
patent: 6831099 (2004-12-01), Crews et al.
patent: 6838252 (2005-01-01), Mundy et al.
patent: 6838436 (2005-01-01), Mundy et al.
patent: 6884769 (2005-04-01), Mundy et al.
patent: 6902721 (2005-06-01), Mundy et al.
patent: 7232818 (2007-06-01), Smyth et al.
patent: 7388017 (2008-06-01), Tung et al.
patent: 7417042 (2008-08-01), Smyth et al.
patent: 7491704 (2009-02-01), Smyth et al.
patent: 7686456 (2010-03-01), Zhou et al.
patent: 7687456 (2010-03-01), Zhou et al.
patent: 7691852 (2010-04-01), Shenk et al.
patent: 7737112 (2010-06-01), Lewis et al.
patent: 2003/0224469 (2003-12-01), Buchholz et al.
patent: 2003/0236223 (2003-12-01), Wagner et al.
patent: 2004/0106539 (2004-06-01), Schubert et al.
patent: 2004/0266664 (2004-12-01), Crews et al.
patent: 2005/0101781 (2005-05-01), Agoulnik et al.
patent: 2005/0245435 (2005-11-01), Smyth et al.
patent: 2005/0256324 (2005-11-01), Laidig et al.
patent: 2006/0030533 (2006-02-01), Smyth et al.
patent: 2006/0088471 (2006-04-01), Bennett et al.
patent: 2006/0128611 (2006-06-01), Lewis
patent: 2006/0241056 (2006-10-01), Orlowski et al.
patent: 2007/0105786 (2007-05-01), Zhou et al.
patent: 2008/0090785 (2008-04-01), Smyth et al.
patent: 2009/0131421 (2009-05-01), Smyth et al.
patent: 2009/0156473 (2009-06-01), Schubert
patent: 2009/0203698 (2009-08-01), Zhou et al.
patent: 2009/0215093 (2009-08-01), Bennett et al.
patent: 2010/0144648 (2010-06-01), Shenk et al.
patent: 2010/0144649 (2010-06-01), Shenk et al.
patent: 0 411 660 (1991-02-01), None
patent: 1 136 498 (2001-09-01), None
patent: WO 91/13904 (1991-09-01), None
patent: WO-94/15956 (1994-07-01), None
patent: WO 95/24914 (1995-09-01), None
patent: WO 96/13266 (1996-05-01), None
patent: WO 96/32105 (1996-10-01), None
patent: WO 98/010779 (1998-03-01), None
patent: WO 00/02548 (2000-01-01), None
patent: WO 00/61167 (2000-10-01), None
patent: WO-01/28579 (2001-04-01), None
patent: WO 03/059898 (2003-07-01), None
patent: WO-2005/105827 (2005-11-01), None
patent: WO 2005/111008 (2005-11-01), None
patent: WO 2005/111009 (2005-11-01), None
patent: WO 2006/017842 (2006-02-01), None
patent: WO-2006/045066 (2006-04-01), None
patent: WO-2006/099261 (2006-09-01), None
patent: WO-2007/056464 (2007-05-01), None
patent: WO 2007/067976 (2007-06-01), None
patent: WO 2007/149512 (2007-12-01), None
patent: WO-2008/140782 (2008-11-01), None
patent: WO-2009/045497 (2009-04-01), None
patent: WO 2010/048298 (2010-04-01), None
Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews (1998), 17, 91-106.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999), vol. 286, 531-537.
European Search Report from EP 08 16 4241 dated Jan. 22, 2009.
Elofsson, M., et al., “Towards Subunit-Specific Proteasome Inhibitors: Synthesis and Evaluation of Peptide α′, α′-Epoxyketones,” Chemistry & Biology, 6(11):811-822 (1999).
International Search Report from PCT/US2006/043503, mailed Feb. 19, 2007.
International Search Report from PCT/US2007/014427, dated Dec. 3, 2007.
International Search Report frorm PCT/US2008/005997, mailed Nov. 7, 2008.
Myung et al., “Lack of Proteasome Active Site Allostery as Revealed by Subunit-Specific Inhibitors,”Molecular Cell, vol. 7, No. 2, pp. 411-420, 2001.
Myung et al., “The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors,”Medicinal Research Reviews, vol. 21, No. 4, pp. 245-273, 2001.
Overkleeft et al., “Solid phase synthesis of peptide vinyl sulfone and peptide epoxyketone proteasome inhibitors,” Tetrahedron Letters, 41(32):6005-6009 (2000).
Sin et al., “Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology”, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 2283-2288, 1999.
Written Opinion of the International Searching Authority for PCT/US2007/014427, dated Dec. 22, 2008.
Caira, “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 198:163-208 (1998).
Groll et al., “Crystal Structure of Epoxomicin:20S Proteasome Reveals a Molecular Basis for Selectivity of α′, β′-Epoxyketone Proteasome Inhibitors,” J. Am. Chem. Soc., 122:1237-1238 (2000).
Vogel's textbook of practical organic chemistry, 5th Ed. See p. 135, “2.20 Recrystallisation Techniques” and p. 141, 2nd paragraph onwards, 1996.
Zhou et al., “Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047),” J. Med. Chem., 52:3028-3038 (2009).
International Search Report and Written Opinion from PCT/US2010/028126 mailed Jun. 9, 2010.
Concise Encyclopedia Chemistry, 1993, p. 490.
Hawley's Condensed Chemical Dictionary, 1993, p. 594.
McGraw-Hill Dictionary of Chemical Terms, 1990, p. 282.
Center for Drug Evaluation and Research, Application No. 21-602, Medical Review, Clinical NDA Review, “NDA 21-602 VELCADE™ (bortexomib) for injection,” Clinical Review, 1-47, 2003.
Center for Drug Evaluation and Research, Application No. 21-602, Medical Review, Clinical NDA Review, “NDA 21-602 VELCADE™ (bortexomib) for injection,” Clinical Review, 81-125, 203.
Center for Drug Evaluation and Research, Application No. 21-602, Medical Review, Clinical NDA Review, “NDA 21-602 VELCADE™ (bortexomib) for injection,” Clinical Review, 1-34, 2003.
“Definition of Cancer,” [Retrieved from] http://www.medterms.com, 1 page [retrieved on Sep. 16, 2005] .
Adams et al., “Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents,”Cancer Research, 1999, 59:2615-2622.
Adams, “The development of proteasome inhibitors as anticancer drugs,”Cancer Cell, May 2003, 5:417-421.
Adams,Cancer Drug Discovery and Development, Protease Inhibitors in Cancer Therapy, 2004. Human Press, Chapter 20, Phase I trials, pp. 271-282.
Almond et al. “The proteasome: a novel target for cancer chemotherapy” Leukemia, 16(4), 433-443, Apr. 2002.
Argiriadi, “Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation,”J. Biol. Chem., 2000, 275(20):15265-15270.
Bao et al. “PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBαdegradation” Am. J. Physiol. Heart Circ. Physiol. 281:H2612-H2618, 2001.
Benedetti et al., “Versatile and Stereoselective Synthesis of Diamino Diol Dipeptide Isosteres, Core Units of Pseudopeptide HIV Protease Inhibitors,”J. Org. Chem., 1997, 62:9348-9353.
Berge et al. “Pharmaceutical Salts”, J. Pharm. Sci. 66(1), 1-
Bennett Mark K.
Laidig Guy J.
Parlati Francesco
Shenk Kevin D.
Smyth Mark S.
Bianchi Kristin
Fish & Richardson P.C.
Onyx Therapeutics, Inc.
Saeed Kamal
LandOfFree
Compounds for enzyme inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for enzyme inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for enzyme inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265954